Streetbeat News

ANPCY

Angle

https://www.angleplc.com/

CEO

Andrew Newland

Industry

Surgical and Medical Instrument Manufacturing

Open

1.95

Mkt cap

60M

Volume

1.2K

High

1.95

P/E Ratio

-2.20

52-wk high

3.35

Low

1.85

Div yield

N/A

52-wk low

0.74

ANGLE PLC has achieved a breakthrough in dual ctDNA and CTC DNA analysis using Illumina's platform, potentially impacting lung cancer diagnostics.

Portfolio Pulse from

February 08, 2025 | 4:15 am

ANGLE PLC's CEO discussed a successful collaboration with Illumina, achieving a breakthrough in dual ctDNA and CTC DNA analysis using Illumina's lung cancer DNA kit. This project could significantly impact cancer diagnostics.

Portfolio Pulse from

January 31, 2025 | 3:30 pm

ANGLE PLC shares increased by 15% following a study that used Illumina's sequencing technology to analyze whole tumor cells in blood, offering a more comprehensive view of cancer than DNA fragments alone.

Portfolio Pulse from

January 29, 2025 | 12:45 pm

ANGLE PLC's Parsortix system was instrumental in a cancer research breakthrough by ETH Zurich, targeting circulating tumor cells in metastatic breast cancer using digoxin.

Portfolio Pulse from

January 24, 2025 | 2:00 pm

ANGLE PLC, a cancer diagnostics firm, is currently undervalued according to Trinity Delta's research. The firm's shares are trading at 11.45p, but the research suggests a valuation of 48p per share, indicating significant potential for growth.

Portfolio Pulse from

January 24, 2025 | 9:45 am

ANGLE PLC is optimistic about 2025, expecting revenue growth to surpass the 31% increase seen in 2024, with £2.9 million in revenue anticipated for the period.

Portfolio Pulse from

January 23, 2025 | 8:30 am

ANGLE PLC presented new data at a cancer research conference, highlighting advances in cancer diagnostics with its Parsortix-based assays for lung and breast cancer.

Portfolio Pulse from

November 15, 2024 | 8:00 am

ANGLE PLC's Parsortix system shows potential in improving treatment tracking and identifying drug-resistant cases in non-small cell lung cancer (NSCLC) by analyzing circulating tumor cells and DNA. The study involved patients treated with AstraZeneca's osimertinib.

Portfolio Pulse from

November 11, 2024 | 7:45 am

ANGLE has signed a supplier agreement with AstraZeneca to develop a Parsortix-based androgen receptor (AR) detection assay for prostate cancer studies, valued at £550,000. The development will occur in ANGLE's UK labs, aiming for completion in Q1 2025. Success could highlight Parsortix's role in evaluating prostate cancer treatments and promise ongoing business for ANGLE in supporting clinical studies.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 7:06 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.